Gabrielle Davis Lacy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabrielle Davis Lacy has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Thiran Jayasundera
Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, 1000 Wall St, Ann Arbor, MI 48105, USA
9 shared publications - David C. Musch
Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA
7 shared publications - Maria Fernanda Abalem
Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA
6 shared publications - Christopher Andrews
Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
4 shared publications Lilia T. Popova
Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA
3 shared publicationsAbigail T. Fahim
Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA
2 shared publications
Latest Publications
- Open Access
- 22 February 2023
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (3) , 218-225
The validation of inherited retinal disease-specific patient-reported outcome measures in adolescent patients
To determine the validity of the validate the adult patient-reported outcome measure tools, the Michigan Retinal Degeneration Questionnaire (MRDQ) and Michigan Vision-Related Anxiety Questionnaire ...
- 22 February 2023
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (3) , 218-225
Open AccessThe validation of inherited retinal disease-specific patient-reported outcome measures in adolescent patients
To determine the validity of the validate the adult patient-reported outcome measure tools, the Michigan Retinal Degeneration Questionnaire (MRDQ) and Michigan Vision-Related Anxiety Questionnaire ...
- 28 November 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (1) , 11-18
Effects of duration and number of symptoms on vision-related anxiety in patients with Inherited Retinal Diseases
Question: How does the duration and number of symptoms that patients with Inherited Retinal Diseases have affect their vision-related anxiety? Findings: In this cross-sectional study of 126 patients with Inherited Retinal Diseases, the number of symptoms, but not the duration of symptoms, was associated with higher vision-related anxiety. Patients with symptoms for longer than 25 years had less vision-related anxiety. Meaning: Patients with more vision-related symptoms may experience more vision-related anxiety.
- 28 November 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (1) , 11-18
Effects of duration and number of symptoms on vision-related anxiety in patients with Inherited Retinal Diseases
Question: How does the duration and number of symptoms that patients with Inherited Retinal Diseases have affect their vision-related anxiety? Findings: In this cross-sectional study of 126 patients with Inherited Retinal Diseases, the number of symptoms, but not the duration of symptoms, was associated with higher vision-related anxiety. Patients with symptoms for longer than 25 years had less vision-related anxiety. Meaning: Patients with more vision-related symptoms may experience more vision-related anxiety.
- 2 January 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 43 (1) , 137-139
Portuguese translation and linguistic validation of the Michigan Retinal Degeneration Questionnaire and the Michigan Vision-Related Anxiety Questionnaire in a cohort with inherited retinal degenerations
Inherited retinal degenerations (IRDs) are among the most important causes of severe visual impairment and blindness in children and young adults in developed countries (1,2), thus posing a signifi...
- 2 January 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 43 (1) , 137-139
Portuguese translation and linguistic validation of the Michigan Retinal Degeneration Questionnaire and the Michigan Vision-Related Anxiety Questionnaire in a cohort with inherited retinal degenerations
Inherited retinal degenerations (IRDs) are among the most important causes of severe visual impairment and blindness in children and young adults in developed countries (1,2), thus posing a signifi...
- 22 August 2021
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 235, 90-97
Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases
- 22 August 2021
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 235, 90-97
Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases
- 6 January 2021
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 42 (2) , 170-177
Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations
Purpose: To identify structural and functional outcome measures among patients with Rho-positive autosomal dominant Retinitis Pigmentosa (adRP) to aid neuroprotection trial design. Methods: This was a retrospective cohort study of 52 patients with Rho-positive adRP. We measured Goldmann Visual Fields (GVF) constriction in four sectors (nasal, temporal, inferior, superior), and sectoral Ellipsoid Zone (EZ) width degeneration using Spectral Domain Optical Coherence Tomography (OCT) scans. Disease progression trajectories were projected using mixed effects modeling. Results: Superior GVF was most constricted at presentation and had the shallowest trajectory (less steep negative slope); Inferior GVF was less constricted (corrected p < .001) and had a steeper negative slope (corrected p = .019) than superior GVF. Temporal EZ was most stable on OCT with a relatively shallow negative trajectory (corrected p = .011). Conclusions: Patients’ superior visual fields presented with more constriction and subsequently had a shallow negative slope suggesting the corresponding inferior retina may be “burned out” at presentation. Targeted therapies for adRP will likely show a greater efficacy signal if delivered to the superior and nasal retina, which may demonstrate more change on OCT and GVF over the course of a neuroprotection trial. Translational Relevance: Mixed effects analysis of sectoral visual field constriction and EZ degeneration in Rho-positive adRP can prove useful in monitoring therapeutic efficacy and identifying targets for local therapies.
- 6 January 2021
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 42 (2) , 170-177
Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations
Purpose: To identify structural and functional outcome measures among patients with Rho-positive autosomal dominant Retinitis Pigmentosa (adRP) to aid neuroprotection trial design. Methods: This was a retrospective cohort study of 52 patients with Rho-positive adRP. We measured Goldmann Visual Fields (GVF) constriction in four sectors (nasal, temporal, inferior, superior), and sectoral Ellipsoid Zone (EZ) width degeneration using Spectral Domain Optical Coherence Tomography (OCT) scans. Disease progression trajectories were projected using mixed effects modeling. Results: Superior GVF was most constricted at presentation and had the shallowest trajectory (less steep negative slope); Inferior GVF was less constricted (corrected p < .001) and had a steeper negative slope (corrected p = .019) than superior GVF. Temporal EZ was most stable on OCT with a relatively shallow negative trajectory (corrected p = .011). Conclusions: Patients’ superior visual fields presented with more constriction and subsequently had a shallow negative slope suggesting the corresponding inferior retina may be “burned out” at presentation. Targeted therapies for adRP will likely show a greater efficacy signal if delivered to the superior and nasal retina, which may demonstrate more change on OCT and GVF over the course of a neuroprotection trial. Translational Relevance: Mixed effects analysis of sectoral visual field constriction and EZ degeneration in Rho-positive adRP can prove useful in monitoring therapeutic efficacy and identifying targets for local therapies.
- 9 December 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 225, 137-146
The Michigan Vision-Related Anxiety Questionnaire: A Psychosocial Outcomes Measure for Inherited Retinal Degenerations
- 9 December 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 225, 137-146
The Michigan Vision-Related Anxiety Questionnaire: A Psychosocial Outcomes Measure for Inherited Retinal Degenerations
- 26 August 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 222, 60-68
The Michigan Retinal Degeneration Questionnaire: A Patient-Reported Outcome Instrument for Inherited Retinal Degenerations
- 26 August 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 222, 60-68
The Michigan Retinal Degeneration Questionnaire: A Patient-Reported Outcome Instrument for Inherited Retinal Degenerations
- 22 June 2020
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 41 (4) , 315-324
Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials
Generate content for a patient-reported outcome (PRO) measure for use in future clinical trials for inherited retinal degenerations. Patients at the University of Michigan Kellogg Eye Center with a...
- 22 June 2020
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 41 (4) , 315-324
Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials
Generate content for a patient-reported outcome (PRO) measure for use in future clinical trials for inherited retinal degenerations. Patients at the University of Michigan Kellogg Eye Center with a...
- Open Access
- 6 January 2020
- Published by Association of University Professors of Ophthalmology in Journal of Academic Ophthalmology
- Vol. 12 (01) , e1-e7
Michigan Ophthalmology Pipeline: Exploring a Mentorship Model to Increase Diversity in Ophthalmology
Background Ethnic concordance between physicians and patients improves compliance and therapeutic benefit. Current literature shows a lack of diversity within ophthalmology. Thus, we aimed to develop a longitudinal mentorship program between first year ophthalmology residents (PGY2s) and first year medical students (M1s) coming from minority communities underrepresented in medicine (URM) to provide early exposure to the field. Methods M1 members of URM organizations were recruited and paired with PGY2 ophthalmology residents in a mentorship program between 2017 and 2019. All participants were surveyed twice annually. Results All 2017 M1s stated increased interest in ophthalmology, felt “satisfied” or “very satisfied” with the program, and completed all requirements. At the year-end, the mean educational value of the program for 2017 M1s was rated 4.33/5, and interest in ophthalmology 4.67/5. Quality of the clinical experiences for 2017 PGY2s 3.5/5, and the overall effectiveness of the program 3.5/5. At the year-end, the average educational value of the program for 2018 M1s was 4.4/5, and interest in ophthalmology 4.0/5. Quality of the clinical experiences for 2018 PGY2s was 3.1/5, and the overall effectiveness of the program was 3.4/5. Conclusion Our “pipeline” program represents an ongoing effort to increase URM interest in ophthalmology. Continued assessment to identify areas for growth and improvement can optimize the program to aid other programs in initiating efforts to tackle this important issue.
- 6 January 2020
- Published by Association of University Professors of Ophthalmology in Journal of Academic Ophthalmology
- Vol. 12 (01) , e1-e7
Open AccessMichigan Ophthalmology Pipeline: Exploring a Mentorship Model to Increase Diversity in Ophthalmology
Background Ethnic concordance between physicians and patients improves compliance and therapeutic benefit. Current literature shows a lack of diversity within ophthalmology. Thus, we aimed to develop a longitudinal mentorship program between first year ophthalmology residents (PGY2s) and first year medical students (M1s) coming from minority communities underrepresented in medicine (URM) to provide early exposure to the field. Methods M1 members of URM organizations were recruited and paired with PGY2 ophthalmology residents in a mentorship program between 2017 and 2019. All participants were surveyed twice annually. Results All 2017 M1s stated increased interest in ophthalmology, felt “satisfied” or “very satisfied” with the program, and completed all requirements. At the year-end, the mean educational value of the program for 2017 M1s was rated 4.33/5, and interest in ophthalmology 4.67/5. Quality of the clinical experiences for 2017 PGY2s 3.5/5, and the overall effectiveness of the program 3.5/5. At the year-end, the average educational value of the program for 2018 M1s was 4.4/5, and interest in ophthalmology 4.0/5. Quality of the clinical experiences for 2018 PGY2s was 3.1/5, and the overall effectiveness of the program was 3.4/5. Conclusion Our “pipeline” program represents an ongoing effort to increase URM interest in ophthalmology. Continued assessment to identify areas for growth and improvement can optimize the program to aid other programs in initiating efforts to tackle this important issue.
- 2 January 2020
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 41 (1) , 1-6
Patient-reported outcome measures in inherited retinal degeneration gene therapy trials
Patient-reported outcome (PRO) measures have the potential to uniquely capture patient experience and serve as an outcome measure in inherited retinal degeneration (IRD) gene therapy trials. An IRD-specific patient-reported outcome measure may yield valuable information that has not been obtained from inherited retinal dystrophy gene therapy trials published to-date. Existing PRO measures have inherent limitations for use in IRD gene therapy trials. Developing an applicable patient-reported outcome measure for such trials needs to incorporate patient input from the target population, demonstrate sound psychometric properties, and be made in accordance with U.S. Food and Drug Administration (FDA) guidelines. This review will discuss the currently available PRO instruments, their limitations for IRD therapeutic trials, and suggestions for future PRO development in IRD populations. The PRO instruments highlighted were identified in PubMed search of English-language journals and previously published review articles.
- 2 January 2020
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 41 (1) , 1-6
Patient-reported outcome measures in inherited retinal degeneration gene therapy trials
Patient-reported outcome (PRO) measures have the potential to uniquely capture patient experience and serve as an outcome measure in inherited retinal degeneration (IRD) gene therapy trials. An IRD-specific patient-reported outcome measure may yield valuable information that has not been obtained from inherited retinal dystrophy gene therapy trials published to-date. Existing PRO measures have inherent limitations for use in IRD gene therapy trials. Developing an applicable patient-reported outcome measure for such trials needs to incorporate patient input from the target population, demonstrate sound psychometric properties, and be made in accordance with U.S. Food and Drug Administration (FDA) guidelines. This review will discuss the currently available PRO instruments, their limitations for IRD therapeutic trials, and suggestions for future PRO development in IRD populations. The PRO instruments highlighted were identified in PubMed search of English-language journals and previously published review articles.